Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy

Kazuhiro Matsumoto, Ryuichi Mizuno, Nobuyuki Tanaka, Hiroki Ide, Masanori Hasegawa, Masaru Ishida, Nozomi Hayakawa, Yota Yasumizu, Masayuki Hagiwara, Satoshi Hara, Eiji Kikuchi, Akira Miyajima, Ken Nakagawa, Yosuke Nakajima, So Nakamura, Jun Nakashima, Mototsugu Oya

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The present study was undertaken to examine biochemical progression in patients who received salvage hormonal therapy (HT) for biochemical disease recurrence (BCR) after radical prostatectomy (RP), and to determine the optimal timing for the administration of HT. The study population consisted of 156 patients who underwent RP and received salvage HT for BCR. The starting point of this study was the timing of RP, and the endpoint was biochemical prostate-specific antigen (PSA) progression (castration-resistance) after HT. The mean follow-up period after surgery was 8.1 years. First, we excluded 18 patients with persistent PSA (≥0.2 ng/mL) after RP from an analysis below because their prognoses were significantly poorer compared with 138 patients whose PSA nadirs had reached <0.2 ng/mL. Multivariate analysis demonstrated that Gleason score ≥8 (p = 0.010, hazard ratio (HR) 3.02), and PSA doubling time (PSA-DT) <6 months (p = 0.001, HR 7.39) was independently associated with subsequent biochemical progression after HT. Using these two variables (Gleason score and PSA-DT), we could stratify patients into three risk groups for BCR after salvage HT. Regarding the optimal timing for HT administration for these high-risk patients with both risk factors (relative risk = 22.3), the PSA cutpoint of 1.0 ng/mL at the initiation of HT showed a significant difference in progression-free survival rates (p = 0.023). The findings indicated that for high-risk patients, salvage HT for BCR after PSA nadir (<0.2 ng/mL) should be started before the PSA level exceeds 1.0 ng/mL; otherwise, there is a significant risk of subsequent biochemical progression after HT.

Original languageEnglish
Article number45
JournalMedical Oncology
Volume31
Issue number7
DOIs
Publication statusPublished - 2014

Fingerprint

Prostate-Specific Antigen
Prostatectomy
Recurrence
Salvage Therapy
Neoplasm Grading
Therapeutics
Castration
Disease-Free Survival
Multivariate Analysis
Survival Rate
Population

Keywords

  • Gleason score
  • Hormonal therapy
  • Prostate cancer
  • PSA doubling time
  • Radical prostatectomy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology

Cite this

Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. / Matsumoto, Kazuhiro; Mizuno, Ryuichi; Tanaka, Nobuyuki; Ide, Hiroki; Hasegawa, Masanori; Ishida, Masaru; Hayakawa, Nozomi; Yasumizu, Yota; Hagiwara, Masayuki; Hara, Satoshi; Kikuchi, Eiji; Miyajima, Akira; Nakagawa, Ken; Nakajima, Yosuke; Nakamura, So; Nakashima, Jun; Oya, Mototsugu.

In: Medical Oncology, Vol. 31, No. 7, 45, 2014.

Research output: Contribution to journalArticle

Matsumoto, K, Mizuno, R, Tanaka, N, Ide, H, Hasegawa, M, Ishida, M, Hayakawa, N, Yasumizu, Y, Hagiwara, M, Hara, S, Kikuchi, E, Miyajima, A, Nakagawa, K, Nakajima, Y, Nakamura, S, Nakashima, J & Oya, M 2014, 'Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy', Medical Oncology, vol. 31, no. 7, 45. https://doi.org/10.1007/s12032-014-0045-1
Matsumoto, Kazuhiro ; Mizuno, Ryuichi ; Tanaka, Nobuyuki ; Ide, Hiroki ; Hasegawa, Masanori ; Ishida, Masaru ; Hayakawa, Nozomi ; Yasumizu, Yota ; Hagiwara, Masayuki ; Hara, Satoshi ; Kikuchi, Eiji ; Miyajima, Akira ; Nakagawa, Ken ; Nakajima, Yosuke ; Nakamura, So ; Nakashima, Jun ; Oya, Mototsugu. / Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy. In: Medical Oncology. 2014 ; Vol. 31, No. 7.
@article{4f5ae270ad69479c889c1a883993db06,
title = "Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy",
abstract = "The present study was undertaken to examine biochemical progression in patients who received salvage hormonal therapy (HT) for biochemical disease recurrence (BCR) after radical prostatectomy (RP), and to determine the optimal timing for the administration of HT. The study population consisted of 156 patients who underwent RP and received salvage HT for BCR. The starting point of this study was the timing of RP, and the endpoint was biochemical prostate-specific antigen (PSA) progression (castration-resistance) after HT. The mean follow-up period after surgery was 8.1 years. First, we excluded 18 patients with persistent PSA (≥0.2 ng/mL) after RP from an analysis below because their prognoses were significantly poorer compared with 138 patients whose PSA nadirs had reached <0.2 ng/mL. Multivariate analysis demonstrated that Gleason score ≥8 (p = 0.010, hazard ratio (HR) 3.02), and PSA doubling time (PSA-DT) <6 months (p = 0.001, HR 7.39) was independently associated with subsequent biochemical progression after HT. Using these two variables (Gleason score and PSA-DT), we could stratify patients into three risk groups for BCR after salvage HT. Regarding the optimal timing for HT administration for these high-risk patients with both risk factors (relative risk = 22.3), the PSA cutpoint of 1.0 ng/mL at the initiation of HT showed a significant difference in progression-free survival rates (p = 0.023). The findings indicated that for high-risk patients, salvage HT for BCR after PSA nadir (<0.2 ng/mL) should be started before the PSA level exceeds 1.0 ng/mL; otherwise, there is a significant risk of subsequent biochemical progression after HT.",
keywords = "Gleason score, Hormonal therapy, Prostate cancer, PSA doubling time, Radical prostatectomy",
author = "Kazuhiro Matsumoto and Ryuichi Mizuno and Nobuyuki Tanaka and Hiroki Ide and Masanori Hasegawa and Masaru Ishida and Nozomi Hayakawa and Yota Yasumizu and Masayuki Hagiwara and Satoshi Hara and Eiji Kikuchi and Akira Miyajima and Ken Nakagawa and Yosuke Nakajima and So Nakamura and Jun Nakashima and Mototsugu Oya",
year = "2014",
doi = "10.1007/s12032-014-0045-1",
language = "English",
volume = "31",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "7",

}

TY - JOUR

T1 - Optimal timing of hormonal therapy for prostate-specific antigen recurrence after radical prostatectomy

AU - Matsumoto, Kazuhiro

AU - Mizuno, Ryuichi

AU - Tanaka, Nobuyuki

AU - Ide, Hiroki

AU - Hasegawa, Masanori

AU - Ishida, Masaru

AU - Hayakawa, Nozomi

AU - Yasumizu, Yota

AU - Hagiwara, Masayuki

AU - Hara, Satoshi

AU - Kikuchi, Eiji

AU - Miyajima, Akira

AU - Nakagawa, Ken

AU - Nakajima, Yosuke

AU - Nakamura, So

AU - Nakashima, Jun

AU - Oya, Mototsugu

PY - 2014

Y1 - 2014

N2 - The present study was undertaken to examine biochemical progression in patients who received salvage hormonal therapy (HT) for biochemical disease recurrence (BCR) after radical prostatectomy (RP), and to determine the optimal timing for the administration of HT. The study population consisted of 156 patients who underwent RP and received salvage HT for BCR. The starting point of this study was the timing of RP, and the endpoint was biochemical prostate-specific antigen (PSA) progression (castration-resistance) after HT. The mean follow-up period after surgery was 8.1 years. First, we excluded 18 patients with persistent PSA (≥0.2 ng/mL) after RP from an analysis below because their prognoses were significantly poorer compared with 138 patients whose PSA nadirs had reached <0.2 ng/mL. Multivariate analysis demonstrated that Gleason score ≥8 (p = 0.010, hazard ratio (HR) 3.02), and PSA doubling time (PSA-DT) <6 months (p = 0.001, HR 7.39) was independently associated with subsequent biochemical progression after HT. Using these two variables (Gleason score and PSA-DT), we could stratify patients into three risk groups for BCR after salvage HT. Regarding the optimal timing for HT administration for these high-risk patients with both risk factors (relative risk = 22.3), the PSA cutpoint of 1.0 ng/mL at the initiation of HT showed a significant difference in progression-free survival rates (p = 0.023). The findings indicated that for high-risk patients, salvage HT for BCR after PSA nadir (<0.2 ng/mL) should be started before the PSA level exceeds 1.0 ng/mL; otherwise, there is a significant risk of subsequent biochemical progression after HT.

AB - The present study was undertaken to examine biochemical progression in patients who received salvage hormonal therapy (HT) for biochemical disease recurrence (BCR) after radical prostatectomy (RP), and to determine the optimal timing for the administration of HT. The study population consisted of 156 patients who underwent RP and received salvage HT for BCR. The starting point of this study was the timing of RP, and the endpoint was biochemical prostate-specific antigen (PSA) progression (castration-resistance) after HT. The mean follow-up period after surgery was 8.1 years. First, we excluded 18 patients with persistent PSA (≥0.2 ng/mL) after RP from an analysis below because their prognoses were significantly poorer compared with 138 patients whose PSA nadirs had reached <0.2 ng/mL. Multivariate analysis demonstrated that Gleason score ≥8 (p = 0.010, hazard ratio (HR) 3.02), and PSA doubling time (PSA-DT) <6 months (p = 0.001, HR 7.39) was independently associated with subsequent biochemical progression after HT. Using these two variables (Gleason score and PSA-DT), we could stratify patients into three risk groups for BCR after salvage HT. Regarding the optimal timing for HT administration for these high-risk patients with both risk factors (relative risk = 22.3), the PSA cutpoint of 1.0 ng/mL at the initiation of HT showed a significant difference in progression-free survival rates (p = 0.023). The findings indicated that for high-risk patients, salvage HT for BCR after PSA nadir (<0.2 ng/mL) should be started before the PSA level exceeds 1.0 ng/mL; otherwise, there is a significant risk of subsequent biochemical progression after HT.

KW - Gleason score

KW - Hormonal therapy

KW - Prostate cancer

KW - PSA doubling time

KW - Radical prostatectomy

UR - http://www.scopus.com/inward/record.url?scp=84901908488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901908488&partnerID=8YFLogxK

U2 - 10.1007/s12032-014-0045-1

DO - 10.1007/s12032-014-0045-1

M3 - Article

C2 - 24913809

AN - SCOPUS:84901908488

VL - 31

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 7

M1 - 45

ER -